✉news BusinessMarkets first seen 15 h ago, last 13 h ago, peak #28
Jury Orders Eli Lilly to Pay Nektar $90 Million
Original: A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved
A jury awarded Nektar Therapeutics $90 million in damages from Eli Lilly, yet Nektar's stock barely moved after the decision. Commentators attribute the muted reaction to the award being small relative to the stakes and uncertainty over whether the verdict will survive appeals. Investors appear to have largely priced in the outcome, with attention staying on Nektar's drug pipeline rather than litigation.
Why now: The verdict is newsworthy but the small award size and appeal uncertainty explain the muted market reaction.
Rank over time, top of the chart is #1. 2 snapshots from 15 h ago to 13 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/2408